Anson K. Abraham

Statistics

Publications

Citations

471

H-Index

Active since

2007

Affiliations

University at Buffalo, State University of New York(Current)

Pfizer (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Amgen (United States)

Anson K. Abraham is an author at University at Buffalo, State University of New York specializing in pharmacology, pharmacokinetics, and pharmacokinetic modeling.

ORCID

Publications per year

2007–2025

Publications

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

Elena Garralda, Ammar Sukari, Nehal J. Lakhani et al. · ESMO Open · 2022 · 88 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition

Aman P. Singh, Wojciech Krzyżański, Steven W. Martin et al. · The AAPS Journal · 2014 · 53 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons

Leonid Kagan, Anson K. Abraham, John M. Harrold et al. · Pharmaceutical Research · 2010 · 48 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

Alberto Visintin, Kelly M. Knowlton, Edyta Tyminski et al. · Molecular Cancer Therapeutics · 2015 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17

Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition

Anson K. Abraham, Wojciech Krzyżański, Donald E. Mager · The AAPS Journal · 2007 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

1–5 of 14